Company Overview

Pharma-Bio Serv, Inc. (PBSV) is a contract research and consulting organization operating within the pharmaceutical, biotechnology, and medical device industries. The company provides regulatory compliance, validation, quality assurance, and technical support services primarily to life sciences manufacturers. Its core business model centers on fee-based professional services that support clients in meeting regulatory standards established by agencies such as the U.S. Food and Drug Administration (FDA).

Founded in 1994, the company evolved from a local technical consulting firm into a specialized service provider supporting regulated manufacturing environments. Pharma-Bio Serv, Inc. is positioned as a niche provider with deep expertise in FDA-regulated operations, particularly in validation and compliance services, and has historically focused on long-term client relationships rather than large-scale project execution.

Business Operations

The company generates revenue through professional services delivered across its primary operating segments, including Validation Services, Quality and Compliance Consulting, and Regulatory Support Services. These services encompass equipment and process validation, quality systems implementation, data integrity consulting, and compliance remediation. Revenue is largely project-based or derived from recurring service agreements with regulated manufacturers.

Operations are conducted through the parent company and its wholly owned subsidiary, PBSV Holdings, Inc., which supports corporate structuring and service delivery. The company does not manufacture products and does not own significant proprietary technologies; instead, it relies on specialized human capital, technical expertise, and regulatory knowledge. Data regarding material joint ventures or equity-method investments is inconclusive based on available public sources.

Strategic Position & Investments

Pharma-Bio Serv, Inc. has historically pursued a conservative growth strategy focused on organic expansion, workforce specialization, and maintaining regulatory expertise aligned with evolving FDA and international compliance standards. Strategic priorities have included expanding service offerings in data integrity, computer system validation, and quality management systems, reflecting regulatory trends within the life sciences sector.

Public disclosures indicate no material acquisitions or large-scale capital investments in recent years. The company has not reported ownership of notable portfolio companies or investments in emerging technologies beyond service capability enhancements. Information on formal long-term growth initiatives is limited, and detailed strategic investment disclosures are inconclusive based on available public sources.

Geographic Footprint

The company is headquartered in Puerto Rico, a major hub for pharmaceutical and medical device manufacturing. Its geographic focus has historically been concentrated in Puerto Rico and the United States, where it supports FDA-regulated facilities operated by multinational life sciences companies.

While Pharma-Bio Serv, Inc. has indicated the ability to support clients with operations outside the continental United States, publicly available information suggests limited permanent international infrastructure. International activities, where present, appear to be project-based rather than supported by dedicated foreign offices.

Leadership & Governance

Pharma-Bio Serv, Inc. was founded by Dr. Daniel A. Santini, who has played a central role in shaping the company’s technical focus and regulatory orientation. Leadership emphasizes regulatory rigor, technical depth, and long-term client partnerships rather than rapid expansion. The company is governed by a small executive team and board consistent with its size and service-based business model.

Key executives include:

• Dr. Daniel A. Santini – Founder, Chairman, and President
• Irma A. Ríos – Vice President of Operations
• Carlos A. González – Chief Financial Officer

Publicly available governance disclosures are limited compared to larger issuers, and detailed information on board committee structures is inconclusive based on available public sources.